Edmond de Rothschild et al. invest €16m in Poxel
Edmond de Rothschild Investment Partners (EdRIP), CDC Entreprises and CrУЉdit Agricole Private Equity have provided biopharma Poxel with a тЌ16m series-A round of financing.
Poxel is a French company developing anti-diabetic molecules; it spun out from Merck Serono in 2009. The new funding will be used to accelerate the development of Poxel's most advanced product, Imeglimine, designed to treat type-2 diabetes.
The unquote" team is currently researching this transaction. In-depth deal information for subscribers will follow shortly.
If you have any information regarding this transaction, please contact Grégoire Gille on +44 20 7484 9824 or gregoire.gille@incisivemedia.com
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds








